SOLENO THERAPEUTICS INC 8-K

What Happened

• Soleno Therapeutics, Inc. (SLNO) announced preliminary financial results and operating metrics for the three months and year ended December 31, 2025 via a press release. The company filed a Form 8-K on January 12, 2026 to furnish that press release (Exhibit 99.1). The 8-K states this information is being furnished under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Filing date: January 12, 2026.
• Reporting periods covered: three months and year ended December 31, 2025.
• Press release is furnished as Exhibit 99.1 to the Form 8-K.
• The Company notes the furnished information under Item 2.02 is not “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference in other filings absent specific reference.

Why It Matters

• Preliminary quarterly and annual results can affect investor expectations about Soleno’s revenue, expenses, cash position, and operational progress. Retail investors should read the Exhibit 99.1 press release for the actual financial figures and metrics and watch for any subsequent updates or audited results in future SEC filings. The legal note that the release is “furnished” (not “filed”) limits certain liabilities and how the information may be incorporated into other filings.